Author: Fiona Craig

ECR Minerals plc (LSE:ECR) said it has assembled an experienced operating team and is preparing to commence initial mining at its recently acquired Raglan alluvial gold project in central Queensland. The company expects first gold production to be achieved before the end of January 2026, marking an important step in its evolution from pure exploration toward cash-generating operations.

Raglan is described as a low-capital, turnkey project, with all essential infrastructure, regulatory approvals and mining equipment already in place. Management believes this positions the operation to deliver early cash flow, which can be reinvested to advance ECR’s larger-scale Blue Mountain project and support development across its broader Queensland asset base. The timing is seen as favourable, with gold prices at historically elevated levels that could enhance both project economics and strategic optionality.

The move into production at Raglan underlines ECR Minerals’ strategy to balance near-term revenue generation with longer-term exploration upside. By leveraging existing assets and permits, the company aims to reduce execution risk while building a platform to fund future growth within its Australian gold portfolio.

More about ECR Minerals

ECR Minerals plc is a UK-listed mineral exploration and development company with a focus on gold projects in Australia. It operates through wholly owned subsidiaries in Victoria and Queensland and holds a diversified portfolio that includes the Bailieston, Creswick and Tambo projects in Victoria, alongside the Raglan and Blue Mountain alluvial gold projects and extensive exploration ground in the Lolworth Range and Kondaparinga areas of Queensland. The group also retains contingent payment rights from previously divested Victorian assets and has significant unutilised tax losses from earlier operations.

Oriole Resources PLC (LSE:ORR) has released initial assay results from its first-ever diamond drilling campaign at the MB01-N target within its 90%-owned Mbe gold project in Cameroon. The 2,950-metre programme has delivered encouraging early results, with the first two drill holes intersecting multiple zones of near-surface gold mineralisation, including 21.7 metres grading 3.13 g/t gold and a standout interval of 1 metre at 42.5 g/t gold.

The company said MB01-N shares strong geological characteristics with the nearby MB01-S deposit, where it has already outlined a JORC Inferred Resource of 870,000 ounces. MB01-N itself hosts a sizeable JORC Exploration Target estimated at between 370,000 and 605,000 ounces. Oriole believes the early high-grade intersections support the potential to upgrade this target into a formal mineral resource.

Drilling at MB01-N is fully funded and now close to 50% complete, with completion expected in the first quarter of 2026. Successful conversion of the exploration target into a defined resource could materially increase the overall scale of the Mbe project, ahead of partner BCM International earning a 50% interest in the licence upon completion of the programme.

From an investment standpoint, Oriole’s outlook continues to be weighed down by the absence of revenue and ongoing cash burn, despite the support of a low-debt balance sheet. Share price technicals are moderately positive, but valuation remains constrained by negative earnings and the lack of dividend support.

More about Oriole Resources PLC

Oriole Resources PLC is an AIM-quoted gold exploration company focused on early-stage projects in West and Central Africa. Its primary area of activity is Cameroon, where it is advancing district-scale orogenic gold opportunities, including the Mbe gold project, through systematic exploration and drilling.

ENGAGE XR Holdings plc (LSE:EXR) said it expects revenue for 2025 to fall sharply to around €1.9 million, down from €3.4 million the previous year, citing delays in contract completions and a marked decline in enterprise customer renewals. The weakness was most pronounced in the second half of the year, as slower global technology hiring weighed on corporate spending decisions.

Despite the drop in turnover, management expects a material improvement in profitability metrics, with the EBITDA loss forecast to narrow to approximately €2.4 million from €4.0 million in 2024. The improvement reflects ongoing cost discipline and operational efficiencies, which also supported a year-end cash position of €1.6 million, ahead of market expectations.

Strategically, ENGAGE XR is accelerating its pivot toward the education market, where usage levels are increasing and larger K-12 customers have expanded their licence commitments. As part of this push, the company has introduced official Chromebook support, enabling it to better address the dominant device used in US classrooms. The group is set to showcase this capability at the Bett Conference in London through a joint demonstration with Lenovo.

The board said it remains focused on conserving cash while evaluating initiatives aimed at enhancing long-term shareholder value. Management believes education markets across schools, universities and home-schooling environments—particularly in the US and the Middle East—offer a more resilient growth path as enterprise demand continues to face headwinds.

Overall, the outlook for ENGAGE XR is constrained by declining revenue and ongoing losses. Technical indicators point to a bearish trend, while valuation metrics remain unattractive due to negative earnings and the absence of dividend support.

More about VR Education Holdings

ENGAGE XR Holdings plc is an AI and spatial computing technology company behind the ENGAGE platform, which delivers immersive virtual and augmented reality environments for education, training and collaboration. The platform is used by enterprise and educational customers globally for onboarding, learning, meetings and product demonstrations, with a growing emphasis on K-12, higher education and home-school markets, particularly in the United States and the Middle East.

GSK (LSE:GSK) said it has achieved positive topline results from its pivotal Phase III B-Well 1 and B-Well 2 studies of bepirovirsen, an investigational antisense oligonucleotide designed as a finite six-month therapy for chronic hepatitis B (CHB). The disease affects more than 250 million people worldwide and is a leading cause of liver cancer. The successful readout marks a significant step toward offering a treatment approach that could move beyond lifelong viral suppression.

The two trials enrolled more than 1,800 patients across 29 countries and met their primary endpoints, demonstrating statistically significant and clinically meaningful functional cure rates when bepirovirsen was added to standard nucleos(t)ide analogue therapy, compared with standard care alone. GSK said the treatment effect was particularly pronounced in patients with lower baseline hepatitis B surface antigen levels, while the overall safety profile was considered acceptable.

Based on these results, GSK plans to begin regulatory submissions globally from early 2026. If approved, bepirovirsen could become the first finite therapy for chronic hepatitis B and serve as a foundation for future sequential treatment strategies. Management believes this could materially strengthen GSK’s hepatology franchise and represent a major shift in how the disease is managed over the long term, with potential benefits for both patients and healthcare systems.

From an investment perspective, GSK’s outlook is supported by its strong financial performance and relatively attractive valuation metrics. Ongoing strategic actions, including share buybacks and sustained investment in research and development, underpin confidence in future growth. These positives are balanced by pressures in certain business segments and ongoing cash flow considerations, suggesting a more measured outlook despite the clinical success.

More about GlaxoSmithKline

GSK is a global biopharmaceutical company focused on developing innovative medicines and vaccines, guided by its aim to get ahead of disease. The group has a growing hepatology pipeline and targets areas of significant unmet medical need, including infectious diseases with large global impact such as chronic hepatitis B.

Directa Plus (LSE:DCTA) reported a modest increase in revenue to €7.0 million for 2025 and a roughly 30% year-on-year improvement in adjusted LBITDA to around €2.5 million, reflecting tighter cost control and operational efficiencies. The group also continued to advance its proprietary technology to manufacture interlocked and blended graphene materials, targeting applications in PFAS-related uses, defence and other highly regulated sectors seen as offering strong growth potential.

Alongside this, Directa Plus pressed ahead with the restructuring of its Setcar subsidiary. Management said the programme has already delivered at least €0.7 million in annualised cost savings and included the award of a €1.5 million Total Waste Management contract with Ford. The group has also launched a process to potentially dispose of non-core land assets, as part of a broader effort to improve capital allocation and enhance shareholder value. Year-end cash stood at €1.5 million, and the board said it is actively pursuing partnerships, joint ventures and licensing opportunities to monetise its patent portfolio, with plans to raise additional funding during 2026.

The update also included changes at board level. Chairman Richard Hickinbotham has stepped down, while chief executive Giulio Cesareo has been appointed interim chairman as the company progresses its CEO succession plans.

Despite the operational progress, Directa Plus’s outlook remains constrained by underlying financial challenges, including continued losses, negative free cash flow and revenue pressure. Technical indicators point to a supportive share price trend, although an overbought RSI suggests some near-term risk. Management commentary from the latest earnings call was more constructive, highlighting revenue initiatives, further cost reductions, increased automation and partnership activity. Valuation, however, continues to be weighed down by ongoing losses and the absence of dividend support.

More about Directa Plus

Directa Plus is an Italy-based producer and supplier of graphene nanoplatelets and graphene-enabled products serving consumer and industrial markets. The company uses a proprietary plasma super expansion process to manufacture sustainable, non-toxic graphene materials in multiple formats. Founded in 2005 and listed on London’s AIM market since 2016, Directa Plus focuses on high-growth, highly regulated sectors through its G+ branded materials and holds the London Stock Exchange’s Green Economy Mark.

Predator Oil & Gas Holdings Plc (LSE:PRD) reported a 19% month-on-month increase in daily oil output from its Trinidad operations, with production reaching 367 barrels of oil per day as at 4 January 2026. The improvement followed the completion of a development well at the Bonasse field and a heavy workover at the Goudron field, both delivered ahead of schedule.

At Bonasse, the BON-17 well successfully accessed a new producing interval with a lower water cut, supporting higher and more efficient output. Meanwhile, the GY-211 workover at Goudron re-entered a previously abandoned reservoir, briefly flowing 221 barrels over a 14-hour period. Management said the result highlights the potential to materially increase production through targeted re-entry of legacy zones. Operational gains have also been supported by infrastructure upgrades, including the installation of a new transformer that reduces diesel consumption and improves lifting efficiency.

With its 2026 work programme now fully funded, Predator is preparing to drill a new high-impact development well and to undertake additional heavy workovers at Goudron. In parallel, the company is advancing regulatory submissions for the Cory Moruga Snowcap-3 appraisal and development well. Management believes these steps validate its recent expansion in onshore Trinidad and position the business to benefit from the area’s rising geopolitical importance and the potential return of major oilfield service providers.

From an investment perspective, the outlook continues to be constrained by the absence of revenue and ongoing losses, alongside negative free cash flow, despite operational improvements during 2024. Technical indicators are broadly supportive, with the share price trading above key moving averages and a positive MACD signal. However, very overbought RSI and stochastic readings introduce near-term risk, while valuation support remains limited due to a negative price-to-earnings ratio and the lack of a stated dividend.

More about Predator Oil & Gas Holdings Plc

Predator Oil & Gas Holdings Plc is a Jersey-based oil and gas company listed on the London Stock Exchange. It operates producing onshore oil assets in Trinidad, where it focuses on production enhancement and infill drilling under a master services agreement with local operator NABI Construction. In Morocco, the company is advancing gas appraisal and development projects targeting shallow biogenic gas, potentially for CNG or micro-LNG solutions, supported by favourable fiscal terms and established gas export infrastructure.

Caspian Sunrise plc (LSE:CASP) said it has convened a General Meeting to be held at 2:00 p.m. on 30 January 2026 at the London offices of Taylor Wessing. At the meeting, shareholders will be asked to formally receive the company’s audited financial statements, together with the directors’ and auditors’ reports, for the year ended 31 December 2024.

The company confirmed that the notice of meeting and the associated shareholder circular are being distributed to investors and have also been published on its website. The announcement reflects Caspian Sunrise’s routine governance and reporting timetable, providing shareholders with the opportunity to review and acknowledge the group’s 2024 financial results in a formal setting.

From a market perspective, Caspian Sunrise’s outlook is supported by positive technical indicators, with the shares trading above key moving averages, alongside a low price-to-earnings ratio that points to potential undervaluation. These strengths are balanced by a mixed underlying financial picture, with profitability weighed against declining revenue and pressures on cash flow. Limited disclosure from earnings calls or recent corporate events restricts additional insight into management’s forward-looking expectations.

More about Caspian Sunrise

Caspian Sunrise plc is a London-listed energy company focused on oil and gas exploration and production. The group maintains a broad shareholder base of institutional and retail investors and provides regular updates through its financial reporting and corporate governance processes.

Solvonis Therapeutics (LSE:SVNS) said it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering a new family of compounds within its SVN-SDN-14 post-traumatic stress disorder (PTSD) discovery programme. The patent milestone enhances the intellectual property protection around the early-stage asset as the company works toward selecting a lead development candidate in the first quarter of 2026.

The newly covered compounds are designed to act across serotonin, dopamine and noradrenaline pathways, while incorporating a mechanism for predictable metabolic deactivation. Solvonis said this approach is intended to provide greater control over pharmacokinetics, potentially enabling safer and more flexible dosing. Management believes these characteristics could improve real-world clinical usability and strengthen both the scientific rationale and commercial appeal of its PTSD programme within the competitive central nervous system (CNS) therapeutics space.

Despite the positive IP development, Solvonis’s overall outlook continues to be constrained by weak financial fundamentals, including the absence of revenue in 2024, ongoing losses and continued cash burn. These pressures are partially mitigated by a low-debt balance sheet. From a market perspective, technical indicators are supportive, with the share price trading above key moving averages and a positive MACD signal, although valuation remains difficult to assess due to the lack of meaningful P/E and dividend yield metrics.

More about Solvonis Therapeutics

Solvonis Therapeutics is a London-headquartered, LSE-listed biopharmaceutical company focused on developing novel small-molecule treatments for high-burden CNS disorders, including addiction, psychiatric and neurological conditions. Its pipeline includes repurposed and newly discovered compounds, led by Phase 3 candidate SVN-001 for severe alcohol use disorder in the UK, SVN-002 preparing for a Phase 2b trial in the US for moderate-to-severe alcohol use disorder, and the preclinical PTSD programme SVN-SDN-14, supported by a broader proprietary CNS compound library.

Blackbird plc (LSE:BIRD) said its browser-based collaborative video editing platform, elevate.io, will integrate the music and sound effects library of Epidemic Sound by the end of the first quarter of 2026. The move will allow users to access a wide range of pre-cleared, royalty-free audio content directly within the editing interface, simplifying workflows and reducing copyright risk for professional and creator-economy users.

Management described the partnership as a meaningful enhancement to elevate.io’s proposition and an early endorsement of its collaborative, cloud-native editing model. Blackbird is targeting growth in the global collaborative video editing market, which it estimates could expand to around $4.5 billion by 2029. For Epidemic Sound, the integration extends its reach further into the creator and professional production ecosystem, strengthening its positioning among users seeking efficient, copyright-safe content creation tools.

Despite the strategic progress, Blackbird’s near-term outlook remains constrained by financial pressures, including ongoing losses, cash burn and declining revenue, alongside bearish share price technicals. These challenges are partially offset by a more constructive tone from recent earnings updates, with management pointing to a pathway toward EBITDA positivity and tighter cash management. Valuation remains difficult to assess given negative earnings and the absence of dividend payments.

More about Blackbird PLC

Blackbird plc operates across the SaaS, media and entertainment, and content creation markets, providing patented cloud-native video technology that supports frame-accurate viewing, navigation and editing directly in the cloud. Its flagship Blackbird® platform is used by broadcasters, rights holders, sports and news organisations, live event producers and post-production specialists. The company’s newer elevate.io platform focuses on browser-based collaborative editing for professional teams and the growing creator economy, while its ‘Powered by Blackbird’ licensing model enables third parties to adopt true cloud video workflows.

Innovative Eyewear, a portfolio company of Tekcapital (LSE:TEK), reported a strong acceleration in sales momentum, posting preliminary unaudited revenue of around $1 million for the fourth quarter of 2025. This represented an increase of approximately 45% compared with the same period a year earlier. For the full year, the company expects revenue of about $2.7 million, marking a 65% rise from 2024.

Growth was driven by robust demand for the Lucyd Armor smart safety eyewear range and the Reebok-branded sports collection. Innovative Eyewear has also expanded its global fulfilment capabilities and now estimates that it holds roughly 44% of Amazon’s smart safety glasses segment. Management’s stated intention to purchase shares in the open market has been highlighted as a signal of confidence in the company’s strategy, as it looks to broaden distribution through major retail and optical chains and capture further upside from the growing smart eyewear market. These developments could translate into additional value for Tekcapital, which holds a significant minority stake.

Despite the top-line progress, the outlook remains constrained by financial challenges, including continued operating and free cash flow losses and revenue that, while growing, remains relatively small and volatile. These concerns are partly offset by a conservative balance sheet with no debt. From a market perspective, technical indicators are moderately supportive, with the share price trading above key moving averages, and valuation metrics appear undemanding on a price-to-earnings basis. However, ongoing cash burn and operational instability continue to temper investor sentiment.

More about Tekcapital

Tekcapital is a UK-based intellectual property investment company listed on London’s AIM market. The group focuses on commercialising university-developed technologies with the potential for real-world impact. One of its portfolio companies is Innovative Eyewear, a US-based developer and manufacturer of ChatGPT-enabled Bluetooth smart glasses sold under brands including Lucyd, Nautica, Eddie Bauer and Reebok. Tekcapital currently owns approximately 4.73% of Innovative Eyewear’s issued share capital.